drugset / Trial / NCT03912857

Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer

NCT03912857 ↗

NaSingle-groupOpen-labelTreatment

Summary

The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.This study was a one-arm, single-center, open clinical study. A total of 50 patients were enrolled in the study.

Timeline

Start
2018-12-01
Primary completion
2019-12-01
Completion
2020-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg —
Subject Rivoceranib Small molecule 250 mg —
Subject Rivoceranib Small molecule 375 mg —

Indications